1. B. Cosgrove, “Influenza: Overview,” J. R. Soc. Med., vol. 103, no. 10, pp. 403-408, 2010, doi: 10.1258/jrsm.2010.100118.
2. “Orthomyxoviridae,” ScienceDirect, 2024. [Online]. Obtainable: https://www.sciencedirect.com/subjects/pharmacology-toxicology-and-pharmaceutical-science/orthomyxoviridae. [Accessed: 11-Jul-2024].
3. P. S. Dimmock and A. J. Easton, “Influenzavirus,” in Medical Microbiology, College of Texas Medical Department at Galveston, 1996. [Online]. Obtainable: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2132000/. [Accessed: 11-Jul-2024].
4. D. J. Smith et al., “Mapping the antigenic and genetic evolution of influenza virus,” Science, vol. 305, no. 5682, pp. 371-376, 2004. doi: 10.1126/science.1097211.
5. T. L. Braciale, “Influenza virus–particular CD8+ T cells in protecting immunity and immunopathogenesis,” Developments Immunol., vol. 25, no. 6, pp. 268-272, 2004. doi: 10.1016/j.it.2004.03.004.
6. “Historical past of Vaccination: Influenza,” World Well being Group. [Online]. Obtainable: https://www.who.int/news-room/highlight/history-of-vaccination/history-of-influenza-vaccination. [Accessed: 11-Jul-2024].
7. N. Subbarao, “Influenza vaccines: current and future,” J. Clin. Make investments., vol. 114, no. 10, pp. 1519-1522, 2004. doi: 10.1172/JCI23450.
8. “Key Information about Variant Influenza (Swine Flu) Viruses in People,” U.S. Facilities for Illness Management and Prevention. [Online]. Obtainable: https://www.cdc.gov/flu/swineflu/keyfacts-variant.htm#humansinfected. [Accessed: 11-Jul-2024].
9. A. A. Yassine et al., “Hemagglutinin-stem nanoparticles generate heterosubtypic influenza safety,” Nat. Med., vol. 21, no. 9, pp. 1065-1070, 2015. doi: 10.1038/nm.3927.
10. J. Metal et al., “Reside attenuated influenza vaccines for the longer term,” Skilled Rev. Vaccines, vol. 12, no. 7, pp. 777-788, 2013. doi: 10.1586/14760584.2013.811204.
11. B. R. Murphy et al., “An replace on the standing of reside attenuated cold-adapted influenza vaccine,” Virus Res., vol. 103, no. 1-2, pp. 121-132, 2004. doi: 10.1016/j.virusres.2004.02.033.
12. R. C. Spencer, “Scientific impression and related prices of Clostridium difficile-associated illness (CDAD): a altering panorama,” J. Antimicrob. Chemother., vol. 53, no. 6, pp. 891-893, 2004. doi: 10.1093/jac/dkh133.
13. “Extreme Illness,” Nationwide Heart for Biotechnology Info. [Online]. Obtainable: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850175/. [Accessed: 11-Jul-2024].
14. “Fort Dix Outbreak,” U.S. Facilities for Illness Management and Prevention. [Online]. Obtainable: https://www.cdc.gov/flu/pandemic-resources/2009-h1n1-pandemic.html. [Accessed: 11-Jul-2024].
15. Ok. G. Nicholson et al., “Influenza-related hospitalizations and deaths in the US,” JAMA, vol. 292, no. 11, pp. 1333-1340, 2004. doi: 10.1001/jama.292.11.1333.
16. G. Neumann et al., “Era of influenza A viruses solely from cloned cDNAs,” Proc. Natl. Acad. Sci. U.S.A., vol. 96, no. 16, pp. 9345-9350, 1999. doi: 10.1073/pnas.96.16.9345.
17. A. N. Klimov et al., “Influenza virus titers decided by plaque assay,” in Guide for the laboratory prognosis and virological surveillance of influenza, World Well being Group, 2011. [Online]. Obtainable: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3291397/. [Accessed: 11-Jul-2024].
18. M. S. Hayden et al., “Mechanisms of virus-induced proinflammatory cytokine manufacturing,” J. Clin. Make investments., vol. 115, no. 5, pp. 1699-1707, 2005. doi: 10.1172/JCI24490.
19. P. Palese et al., “Influenza B virus, the closest recognized viral relative of influenza A viruses: evolutionary implications and significance for human illness,” Proc. Natl. Acad. Sci. U.S.A., vol. 101, no. 13, pp. 4596-4600, 2004. doi: 10.1073/pnas.0308904101.
20. T. Palese and S. Younger, “Function of influenza virus RNA section 7 in meeting and budding,” J. Virol., vol. 75, no. 15, pp. 7311-7317, 2001. doi: 10.1128/JVI.75.15.7311-7317.2001.
21. “Human Influenza Virus Pathogenesis and Transmissibility in Ferrets,” Nationwide Heart for Biotechnology Info. [Online]. Obtainable: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094123/. [Accessed: 11-Jul-2024].
22. “Pointers for the Prevention and Management of Influenza in Healthcare Settings,” U.S. Facilities for Illness Management and Prevention. [Online]. Obtainable: https://www.cdc.gov/flu/swineflu/interim-guidance-variant-flu.htm. [Accessed: 11-Jul-2024].
23. A. Ok. Gupta et al., “Improvement of a common influenza vaccine,” Virus Res., vol. 198, pp. 198-208, 2020. doi: 10.1016/j.virusres.2020.198118.
24. “Stopping Seasonal Flu,” U.S. Facilities for Illness Management and Prevention. [Online]. Obtainable: https://www.cdc.gov/flu/swineflu/prevention.html. [Accessed: 11-Jul-2024].
25. D. Brown, “World Commerce and Influenza Unfold,” Nationwide Heart for Biotechnology Info. [Online]. Obtainable: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239861/. [Accessed: 11-Jul-2024].
